KELSEY NICOLE 4

What Happened Kelsey Nicole, Chief Legal Officer of AVITA Medical, received equity awards on February 18, 2026 totaling 243,450 restricted stock units (RSUs) — 98,390 RSUs (reported with no per‑share price) and 145,060 RSUs reported as a derivative award at $0.00. These RSUs represent contingent rights to be issued common stock and were granted as awards (transaction code A); no cash was exchanged.

Key Details

• Transaction date: February 18, 2026; Form 4 filed February 19, 2026 (timely).
• Grants: 98,390 RSUs (price N/A) and 145,060 RSUs (reported at $0.00, derivative).
• Total new RSUs: 243,450.
• Shares owned after the transaction: not specified in the filing.
• Relevant footnotes:
  • F1/F2: The RSUs are time‑based and vest in three equal annual installments beginning 12 months after the grant date (first vesting on Feb 18, 2027); these include unvested RSUs.
  • F3 is included in the filing text about option vesting schedules (three equal annual installments starting one year after grant) but no option grants are reported in these transactions.
• Transaction type: Award/grant (not a purchase or sale).

Context RSUs are typically retention/compensation awards and are unvested immediately after grant; they do not represent marketable shares until vesting and issuance. Because no cash was paid and the awards vest over time, this is not an immediate liquidity event or market sale — it’s a standard executive compensation grant.